Влияние пандемии COVID-19 на людей с психическими заболеваниями
Рекомендуемое оформление библиографической ссылки:
Соловьева К.П., Морозова И.О., Савенкова В.И., Зоркина Я.А., Абрамова О.В., Очнева А.Г., Ушакова В.М., Лапук Д.Д., Костюк Г.П. Влияние пандемии COVID-19 на людей с психическими заболеваниями // Российский психиатрический журнал. 2023. №2. С. 86-100.
В научном обзоре с целью выявления особенностей влияния пандемии COVID-19 на пациентов с психическими расстройствами предпринята попытка обобщить данные имеющихся на сегодняшний день исследований. Были отобраны 75 статей, описывающие изменения образа жизни пациентов с психическими расстройствами в период пандемии, особенности течения новой коронавирусной инфекции у данной когорты больных, возникающие психические и соматические осложнения, сложности подбора терапии, ее побочные эффекты на фоне вирусного заболевания, проблемы взаимодействия психофармакотерапии и противовирусных препаратов. Полученные результаты свидетельствуют о существенном влиянии коронавирусной инфекции на пациентов с психическими заболеваниями, подтверждают необходимость учета фактора COVID-19 при выстраивании плана диагностических, лечебных и реабилитационных мероприятий.
Ключевые слова COVID-19; психиатрия; нейропсихиатрия; психические нарушения
1. Majumder J, Minko T. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. AAPS J. 2021;23(1):14. DOI: https://doi.org/10.1208/s12248-020-00532-2 2. World Health Organization. Novel coronavirus (2019-nCoV): situation report, 1. Geneva: World Health Organization; 2020. URL: https://apps.who.int/iris/handle/10665/330760 (accessed on: 03.04.2023). 3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44. DOI: https://doi.org/10.1038/s41564-020-0695-z 4. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people with severe mental illness: English record linkage studies. Thorax. 2013;68(2):171–6. DOI: https://doi.org/10.1136/thoraxjnl-2012-202480 5. Mohan M, Perry BI, Saravanan P, Singh SP. COVID-19 in People With Schizophrenia: Potential Mechanisms Linking Schizophrenia to Poor Prognosis. Front Psychiatry. 2021;12:666067. DOI: https://doi.org/10.3389/fpsyt.2021.666067 6. Sartorious N. Comorbidity of mental and physical diseases: a main challenge for medicine of the 21st century. Shanghai Arch Psychiatry. 2013;25(2):68–9. DOI: https://doi.org/10.3969/j.issn.1002-0829.2013.02.002 7. Yazıcı S, Ahi ES, İlhan RS, Saka MC. The effect of the COVID-19 pandemic on health behavior and psychopathology in patients with psychotic disorders. Psychiatry Res. 2022;317:114845. DOI: https://doi.org/10.1016/j.psychres.2022.114845 8. Yao H, Chen JH, Xu YF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21. DOI: https://doi.org/10.1016/S2215-0366(20)30090-0 9. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398(10312):1700–12. DOI: https://doi.org/10.1016/S0140-6736(21)02143-7 10. Song H, Fall K, Fang F, et al. Stress related disorders and subsequent risk of life threatening infections: population based sibling controlled cohort study. BMJ. 2019;367:l5784. DOI: https://doi.org/10.1136/bmj.l5784 11. Pedersen A, Zachariae R, Bovbjerg DH. Influence of psychological stress on upper respiratory infection – a meta-analysis of prospective studies. Psychosom Med. 2010;72(8):823–32. DOI: https://doi.org/10.1097/PSY.0b013e3181f1d003 12. Severance EG, Dickerson FB, Viscidi RP, et al. Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms. Schizophr Bull. 2011;37(1):101–7. DOI: https://doi.org/10.1093/schbul/sbp052 13. Cipriani G, Danti S, Nuti A, et al. A complication of coronavirus disease 2019: delirium. Acta Neurol Belg. 2020;120(4):927–32. DOI: https://doi.org/10.1007/s13760-020-01401-7 14. Wang H, Lu J, Zhao X, et al. Alzheimer's disease in elderly COVID-19 patients: potential mechanisms and preventive measures. Neurol Sci. 2021;42(12):4913–20. DOI: https://doi.org/10.1007/s10072-021-05616-1 15. Wang Q, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2021;20(1):124–30. DOI: https://doi.org/10.1002/wps.20806 16. Lee SW, Yang JM, Moon SY, et al. Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7(12):1025–31. DOI: https://doi.org/10.1016/S2215-0366(20)30421-1 17. Kozloff N, Mulsant BH, Stergiopoulos V, Voineskos AN. The COVID-19 Global Pandemic: Implications for People With Schizophrenia and Related Disorders. Schizophr Bull. 2020;46(4):752–7. DOI: https://doi.org/10.1093/schbul/sbaa051 18. Chen F, Chen Y, Wang Y, et al. The COVID-19 pandemic and Alzheimer's disease: mutual risks and mechanisms. Transl Neurodegener. 2022;11(1):40. DOI: https://doi.org/10.1186/s40035-022-00316-y 19. Rahman MA, Islam K, Rahman S, Alamin M. Neurobiochemical Cross-talk Between COVID-19 and Alzheimer's Disease. Mol Neurobiol. 2021;58(3):1017–23. DOI: https://doi.org/10.1007/s12035-020-02177-w 20. Xia X, Wang Y, Zheng J. COVID-19 and Alzheimer's disease: how one crisis worsens the other. Transl Neurodegener. 2021;10(1):15. DOI: https://doi.org/10.1186/s40035-021-00237-2 21. Courtenay K, Perera B. COVID-19 and people with intellectual disability: impacts of a pandemic. Ir J Psychol Med. 2020;37(3):231–6. DOI: https://doi.org/10.1017/ipm.2020.45 22. O'Leary L, Hughes-McCormack L, Dunn K, Cooper SA. Early death and causes of death of people with Down syndrome: A systematic review. J Appl Res Intellect Disabil. 2018;31(5):687–708. DOI: https://doi.org/10.1111/jar.12446 23. Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100–6. DOI: https://doi.org/10.1016/j.bbi.2020.04.069 24. Favreau M, Hillert A, Osen B, et al. Psychological consequences and differential impact of the COVID-19 pandemic in patients with mental disorders. Psychiatry Res. 2021;302:114045. DOI: https://doi.org/10.1016/j.psychres.2021.114045 25. Palomar-Ciria N, Blanco Del Valle P, Hernández-Las Heras MÁ, Martínez-Gallardo R. Schizophrenia and COVID-19 delirium. Psychiatry Res. 2020;290:113137. DOI: https://doi.org/10.1016/j.psychres.2020.113137 26. Barlati S, Nibbio G, Vita A. Schizophrenia during the COVID-19 pandemic. Curr Opin Psychiatry. 2021;34(3):203–10. DOI: https://doi.org/10.1097/YCO.0000000000000702 27. Ma J, Hua T, Zeng K, et al. Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study. Transl Psychiatry. 2020;10(1):411. DOI: https://doi.org/10.1038/s41398-020-01098-5 28. Llach CD, Vieta E. Mind long COVID: Psychiatric sequelae of SARS-CoV-2 infection. Eur Neuropsychopharmacol. 2021;49:119–21. DOI: https://doi.org/10.1016/j.euroneuro.2021.04.019 29. McLoughlin J, O'Grady MM, Hallahan B. Impact of the COVID-19 pandemic on patients with pre-existing mood disorders. Ir J Psychol Med. 2021;39(4);363–72. DOI: https://doi.org/10.1017/ipm.2021.38 30. Diaz AD, Baweja R. The role of neurotropism in psychiatric patients with COVID-19. Eur Arch Psychiatry Clin Neurosci. 2021;271(2):385–6. DOI: https://doi.org/10.1007/s00406-020-01197-w 31. Moni MA, Lin PI, Quinn J, Eapen V. COVID-19 patient transcriptomic and genomic profiling reveals comorbidity interactions with psychiatric disorders. Transl Psychiatry. 2021;11(1):160. DOI: https://doi.org/10.1038/s41398-020-01151-3 32. Toubasi AA, AbuAnzeh RB, Tawileh H, et al. A meta-analysis: The mortality and severity of COVID-19 among patients with mental disorders. Psychiatry Res. 2021;299:113856. DOI: https://doi.org/10.1016/j.psychres.2021.113856 33. Tzur Bitan D, Krieger I, Kridin K, et al. COVID-19 Prevalence and Mortality Among Schizophrenia Patients: A Large-Scale Retrospective Cohort Study. Schizophr Bull. 2021;47(5):1211–7. DOI: https://doi.org/10.1093/schbul/sbab012 34. Fond G, Pauly V, Orleans V, et al. Increased in-hospital mortality from COVID-19 in patients with schizophrenia. Encephale. 2021;47(2):89–95. DOI: https://doi.org/10.1016/j.encep.2020.07.003 35. Nemani K, Li C, Olfson M, et al. Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. JAMA Psychiatry. 2021;78(4):380–6. DOI: https://doi.org/10.1001/jamapsychiatry.2020.4442 36. Fond G, Pauly V, Leone M, et al. Mortality among inpatients with bipolar disorders and COVID-19: a propensity score matching analysis in a national French cohort study. Psychol Med. 2023;53(5):1979–88. DOI: https://doi.org/10.1017/S0033291721003676 37. Karaoulanis SE, Christodoulou NG. Do patients with schizophrenia have higher infection and mortality rates due to COVID-19? A systematic review. Psychiatriki. 2021;32(3):219–23. DOI: https://doi.org/10.22365/jpsych.2021.027 38. Courtenay K, Cooper V. Covid 19: People with learning disabilities are highly vulnerable. BMJ. 2021;374:n1701. DOI: https://doi.org/10.1136/bmj.n1701 39. Fond G, Nemani K, Etchecopar-Etchart D, et al. Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(11):1208–17. DOI: https://doi.org/10.1001/jamapsychiatry.2021.2274 40. Fornaro M, De Prisco M, Billeci M, et al. Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. J Affect Disord. 2021;295:740–51. DOI: https://doi.org/10.1016/j.jad.2021.08.091 41. Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between Mental Disorders and Subsequent Medical Conditions. N Engl J Med. 2020;382(18):1721–31. DOI: https://doi.org/10.1056/NEJMoa1915784 42. Yong N, Pan J, Li X, et al. Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study. Eur J Med Res. 2022;27(1):90. DOI: https://doi.org/10.1186/s40001-022-00706-y 43. Liang J, Cai Y, Xue X, et al. Does Schizophrenia Itself Cause Obesity? Front Psychiatry. 2022;13:934384. DOI: https://doi.org/10.3389/fpsyt.2022.934384 44. Perry C, Guillory TS, Dilks SS. Obesity and Psychiatric Disorders. Nurs Clin North Am. 2021;56(4):553–63. DOI: https://doi.org/10.1016/j.cnur.2021.07.010 45. Morais AHA, Passos TS, de Lima Vale SH, et al. Obesity and the increased risk for COVID-19: mechanisms and nutritional management. Nutr Res Rev. 2021;34(2):209–21. DOI: https://doi.org/10.1017/S095442242000027X 46. Zhand N, Joober R. Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review. BJPsych Open. 2021;7(1):e35. DOI: https://doi.org/10.1192/bjo.2020.157 47. Mongan D, Cannon M, Cotter DR. COVID-19, hypercoagulation and what it could mean for patients with psychotic disorders. Brain Behav Immun. 2020;88:9–10. DOI: https://doi.org/10.1016/j.bbi.2020.05.067 48. Nguyen TT, Dev SI, Chen G, et al. Abnormal levels of vascular endothelial biomarkers in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2018;268(8):849–60. DOI: https://doi.org/10.1007/s00406-017-0842-6 49. Gordon MN, Heneka MT, Le Page LM, et al. Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research. Alzheimers Dement. 2022;18(5):1038–46. DOI: https://doi.org/10.1002/alz.12488 50. Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Curr Neuropharmacol. 2018;16(8):1210–23. DOI: https://doi.org/10.2174/1570159X15666170630163616 51. Garcia-Ribera C, Carrasco M, Ruiz-Ripoll A. Covid-19, hypercoagulability and risk of mortality in schizophrenia. Actas Esp Psiquiatr. 2021;49(4):194–5. PMID: 34195973 52. Ruan CJ, Zang YN, Cheng YH, et al. Around 3% of 1,300 Levels Were Elevated during Infections in a Retrospective Review of 131 Beijing Hospital In-Patients with More than 24,000 Days of Clozapine Treatment. Psychother Psychosom. 2020;89(4):255–7. DOI: https://doi.org/10.1159/000506355 53. Tio N, Schulte PFJ, Martens HJM. Clozapine Intoxication in COVID-19. Am J Psychiatry. 2021;178(2):123–7. DOI: https://doi.org/10.1176/appi.ajp.2020.20071039 54. Anmella G, Arbelo N, Fico G, et al. COVID-19 inpatients with psychiatric disorders: Real-world clinical recommendations from an expert team in consultation-liaison psychiatry. J Affect Disord. 2020;274:1062–7. DOI: https://doi.org/10.1016/j.jad.2020.05.149 55. Plasencia-García BO, Rico-Rangel MI, Rodríguez-Menéndez G, et al. Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. Pharmacopsychiatry. 2022;55(1):40–7. DOI: https://doi.org/10.1055/a-1492-3293 56. Uvais NA. The Risks of Prescribing Hydroxychloroquine in COVID-19-Infected Patients With Schizophrenia. Prim Care Companion CNS Disord. 2020;22(3):20com02635. DOI: https://doi.org/10.4088/PCC.20com02635 57. Khandaker GM, Cousins L, Deakin J, et al. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry. 2015;2(3):258–70. DOI: https://doi.org/10.1016/S2215-0366(14)00122-9 58. Vancampfort D, Wampers M, Mitchell AJ, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50. DOI: https://doi.org/10.1002/wps.20069 59. Pillinger T, D'Ambrosio E, McCutcheon R, Howes OD. Correction to: Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models. Mol Psychiatry. 2019;24(6):928. DOI: https://doi.org/10.1038/s41380-018-0275-2 60. Almutairi MM, Sivandzade F, Albekairi TH, et al. Neuroinflammation and Its Impact on the Pathogenesis of COVID-19. Front Med (Lausanne). 2021;8:745789. DOI: https://doi.org/10.3389/fmed.2021.745789 61. Steardo LJr, Steardo L, Scuderi C. Astrocytes and the Psychiatric Sequelae of COVID-19: What We Learned from the Pandemic. Neurochem Res. 2023;48:1015–25. DOI: https://doi.org/10.1007/s11064-022-03709-7 62. Stefano GB, Büttiker P, Weissenberger S, et al. Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19. Curr Neuropharmacol. 2022;20(6):1229–40. DOI: https://doi.org/10.2174/1570159X20666211223130228 63. Pomilio AB, Vitale AA, Lazarowski AJ. COVID-19 and Alzheimer's Disease: Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved. Curr Med Chem. 2023;30(35):3993–4031. DOI: https://doi.org/10.2174/0929867329666221003101548 64. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758–63. DOI: https://doi.org/10.1038/s41586-022-05542-y 65. Meinhardt J, Radke J, Dittmayer C, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168–75. DOI: https://doi.org/10.1038/s41593-020-00758-5 66. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268(9):3059–71. DOI: https://doi.org/10.1007/s00415-021-10406-y 67. Rai SN, Tiwari N, Singh P, et al. Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease. Oxid Med Cell Longev. 2022;2022:3012778. DOI: https://doi.org/10.1155/2022/3012778 68. Xia J, Chen S, Li Y, et al. Immune Response Is Key to Genetic Mechanisms of SARS-CoV-2 Infection With Psychiatric Disorders Based on Differential Gene Expression Pattern Analysis. Front Immunol. 2022;13:798538. DOI: https://doi.org/10.3389/fimmu.2022.798538 69. Liu N, Tan JS, Liu L, et al. Genetic Predisposition Between COVID-19 and Four Mental Illnesses: A Bidirectional, Two-Sample Mendelian Randomization Study. Front Psychiatry. 2021;12:746276. DOI: https://doi.org/10.3389/fpsyt.2021.746276 70. Chen W, Zeng Y, Suo C, et al. Genetic predispositions to psychiatric disorders and the risk of COVID-19. BMC Med. 2022;20(1):314. DOI: https://doi.org/10.1186/s12916-022-02520-z 71. Warner FJ, Rajapaksha H, Shackel N, Herath CB. ACE2: from protection of liver disease to propagation of COVID-19. Clin Sci (Lond). 2020;134(23):3137–58. DOI: https://doi.org/10.1042/CS20201268 72. Nadalin S, Jakovac H, Peitl V, et al. Dysregulated inflammation may predispose patients with serious mental illnesses to severe COVID 19 (Review). Mol Med Rep. 2021;24(2):611. DOI: https://doi.org/10.3892/mmr.2021.12250 73. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–60. DOI: https://doi.org/10.1080/22221751.2020.1746200 74. Wincewicz D, Braszko JJ. Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders. Pharmacopsychiatry. 2017;50(6):233–47. DOI: https://doi.org/10.1055/s-0043-112345 75. Ren AL, Digby RJ, Needham EJ. Neurological update: COVID-19. J Neurol. 2021;268(11):4379–87. DOI: https://doi.org/10.1007/s00415-021-10581-y
Метрики статей
Metrics powered by PLOS ALM